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Abstract 
Bruton’s tyrosine kinase (BTK) has recently emerged as an attractive therapeutic target in 
hematologic malignancies. Ibrutinib, the first in class BTK inhibitor, improves survival and is 
well tolerated in patients. Here, we investigate a novel BTK inhibitor, GDC-0853, to evaluate its 
efficacy in chronic lymphocytic leukemia (CLL). GDC-0853 is unique among BTK inhibitors in 
that it utilizes a novel allosteric binding site, different from the C481 kinase domain to which 
ibrutinib irreversibly binds. Like ibrutinib, GDC-0853 blocks B cell receptor signaling, modestly 
reduces viability, prevents stromal and cytokine induced survival, and limits activation in CLL 
lymphocytes through the inhibition of BTK. We found that due to its novel site of action, GDC-
0853 also inhibits C481S mutated BTK in an in vitro system. GDC-0853 is more selective for 
BTK than is ibrutinib which also irreversibly inhibits interleukin-2 inducible kinase (ITK), a Tec 
kinase responsible for T and NK cell activation. The selectivity of GDC-0853 preserves ITK 
function in T and NK cells. Unlike ibrutinib, upper-physiologic concentrations of GDC-0853 had 
no effect on T cell activation or NK cell antibody dependent cell mediated cytotoxicity (ADCC). 
Our results indicate that the GDC-0853 may be an effective therapy for use in CLL as 
monotherapy or in combination with anti-CD20 antibodies, especially among the emerging 
population of patients who are resistant to first generation BTK inhibitors. 
Introduction  
Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia, with an annual 
incidence of over 16,000 individuals in the United States. Bruton’s tyrosine kinase (BTK) has 
recently emerged as an attractive therapeutic target in hematologic malignancies. BTK serves to 
potentiate signaling from proximal receptors. Although its function is identical between healthy 
and malignant B cells, BTK is over-expressed at the transcript level and constitutively active in 
CLL (add references).  BTK dependent pathways are initiated at the B cell receptor (BCR), toll-
like receptors (TLRs), chemokine receptors and a variety of cytokine receptors which contribute 
to canonical and non-canonical NF-kB signaling. Mouse models which overexpress BTK 
through a B cell specific promotor are associated with increased mortality due to a CLL-like 
disease. B lymphocytes from these mice are hyperresponsive to BCR stimulation and 
demonstrate resistance to Fas-mediated apoptosis. Taken together, these findings implicate BTK 
as a driver of CLL pathology.  
Ibrutinib, the first in class BTK inhibitor, is approved for the treatment of CLL, mantle cell 
lymphoma, and waldenstrom macroglobulinemia. Ibrutinib is well tolerated in patients and has 
shown outstanding clinical activity in both relapsed and treatment-naïve CLL, even in those with 
high risk cytogenetic abnormalities.  The clinical success of ibrutinib validates BTK inhibition as 
a powerful therapeutic model in hematologic malignancies. Ibrutinib irreversibly binds to and 
inhibits BTK at its C481 active site, a domain conserved among TEC family kinases. Despite the 
widespread success of ibrutinib, current BTK inhibitor therapy is imperfect and resistance has 
been reported. Acquired resistance to ibrutinib is most commonly mediated by mutation of the 
C481 amino acid of BTK to which ibrutinib irreversibly binds. These mutations prevent 
ibrutinib’s irreversible inhibition of BTK and greatly diminish its potency.  
Additionally, nonspecific recognition of the TEC family active site by ibrutinib leads to the 
inhibition of alternative targets including ITK, a tyrosine kinase responsible for T and NK cell 
activation. Inhibition of ITK by ibrutinib has been shown to inhibit specific T helper cell 
populations and limit the efficacy of antibody dependent cell mediated cytotoxicity (ADCC) by 
NK cells. Ibrutinib’s inhibition of ITK prevents this BTK inhibitor from being effectively 
combined with clinically established antibody therapies which rely upon NK cell mediated 
ADCC.  
Here we characterize a novel, reversible BTK inhibitor, GDC-0853, with a unique mode of 
inhibition. Rather than inhibiting BTK through its C481 active site like ibrutinib, GDC-0853 
utilizes an allosteric binding pocket to exert its inhibitory effects. Because GDC-0853 does not 
rely upon C481, we hypothesized that this compound would maintain efficacy in ibrutinib 
resistance mediated by C481S mutations.  This will establish for the first time in CLL, the 
potential of circumventing ibrutinib resistance through the use of an alternative BTK inhibitor. 
As well, we hypothesized that because it does not bind ITK through the conserved C481 site, that 
GDC-0853 would not limit T cell activation or NK cell mediated ADCC.  
Methods 
Subject Population and Lymphocyte Isolation 
Unless otherwise noted all studies used cells isolated from the whole blood of CLL patients at 
our institution who consented to an IRB-approved tissue procurement protocol or who were 
included on IRB approved clinical trials of ibrutinib in CLL.   Peripheral blood mononuclear 
cells (PBMCs) were isolated from whole blood through ficoll density gradient centrifugation.  
Specific leukocyte populations were negatively selected using Rosette-sep isolation from whole 
blood or Easy-sep negative selection from PBMCs.   
Cell Culture and Drugging 
To specifically inhibit the irreversible targets of ibrutinib, ibrutinib treatment occurred for 1 hour 
followed by washout in which the cells were pelleted and resuspended in fresh 10% FBA RPMI-
1640 media. Cells treated with vehicle or GDC-0853 were similarly pelleted and resuspended in 
10% FBS RPMI-1640 media containing vehicle or GDC-0853. Experiments which occurred over 
several days were treated with daily drugging and media replacement. 
BCR Signaling Immunoblot 
CLL cells treated with BTK inhibitor were stimulated by spinning onto a six-well plate coated 
with anti-IgM antibody at 10ug/mL. Following fifteen minutes of stimulation, cells were lysed 
using a standard protein lysis buffer containing phosphatase and protease inhibitors. Immunoblot 
experiments were conducted by SDS-PAGE. Blots were probed with appropriate primary 
antibodies and HRP-conjugated secondary antibodies and visualized with chemiluminescent 
substrate on X-ray film. Densitometry analysis was performed using AlphaView software. 
Viability Analysis 
Primary CLL cells were assessed for survival 48hrs following treatment with BTK inhibitor. 
Viability was defined as the percentage of PBMCs staining negative for 7AAD. For co-culture 
experiments, stromal cells were stably transfected with green fluorescent protein (GFP) allowing 
us to selectively gate on our GFP-negative CLL population in addition to gates based on cell 
size. Samples with viabilities below 40% at 48hrs were omitted from analysis due to their rapid 
rate of ex-vivo apoptosis and unpredictable behavior in vitro.  All viability measurements were 
acquired with a Beckman Coulter FC3000 flow cytometer. 
CpG induced activation 
Following BTK inhibitor treatment CLL cells were stimulated with 3.2ug CpG/mL. Subsequent 
expression of CD86 was measured by determining Mean Fluorescence Intensity (MFI) after 48 
hrs. Staining intensity of CD86-PE was measured using a Beckman Coulter FC3000 flow 
cytometer. 
T cell immunoblot 
Healthy human T cells were stimulated for 45 minutes with a combination of 2ug/mL plate 
bound anti-CD3 and 10ug/mL soluble anti-CD28. Nuclear and cytoplasmic lysates were 
collected using a ThermoScientific NE-PER kit and analyzed by SDS-PAGE as previously 
described. 
NK cell mediated ADCC 
Effector NK cells were isolated from Leukopaks obtained through the American Red Cross and 
incubated with target CLL cells loaded with radioactive Cr51 at an effector to target ratio of 
25:1. Following treatment of purified NK cells with vehicle, GDC-0853, or ibrutinib for 1 hour, 
CLL cells were incubated with antibody at a concentration of 10ug/mL and co-cultured with NK 
cells to allow for lysis. After 4 hours of co-culture, supernatant was collected and measured for 
radiation using a PerkinElmer Wizard2 gamma counter. These radiation measurements were 
scaled according to a no NK cell co-culture group with baseline CLL lysis and a detergent 
treated CLL group with complete lysis. 
Statistical Analysis 
A mixed effect model provided by A.L. was used for statistical analysis.  
Results 
GDC-0853 effectively inhibits BTK  
To investigate the effect of GDC-0853 on BCR signaling, purified PBMCs from CLL patients 
were treated with drug for 1 hour and then stimulated with anti-IgM antibody for 15 minutes. 
Treatment with GDC-0853 inhibited BTK phosphorylation and downstream activation of 
PLCg2, AKT and ERK similar to the inhibition seen with ibrutinib (Figure 1). Inhibition was 
dose-dependent but was present even at low concentrations of GDC-0853.   
BTK inhibitors have been shown to possess modest levels of direct cytotoxicity against 
malignant CLL B cells. To characterize the cytotoxic potential of GDC-0853, primary CLL cells 
were treated with BTK inhibitor and assessed for changes in viability. After 48 hours, the 
viability of primary CLL cells treated with GDC-0853 was 61.8%, a statistically significant 
reduction compared to the vehicle treated viability of 68.4% (Figure 2A). To determine if GDC-
0853 maintained efficacy in a model of the bone marrow microenvironment, primary CLL cells 
were co-cultured with the human HS5 stromal cell line. GDC-0853 remained cytotoxic in the 
presence of HS5 stromal cells (Figure 2B). Furthermore, absolute viability following treatment 
with GDC-0853 did not differ between the media and co-culture conditions (p=0.386), 
suggesting that GDC-0853 may abrogate the survival benefit of the bone marrow 
microenvironment in addition to its direct cytotoxicity. To test this we sought to determine if 
GDC-0853 negatively affected survival in the presence of various stimulatory cytokines. Anti-
IgM, CD40L, and BAFF are potent activators of both the canonical and non-canonical NFkB 
pathways. As expected from our stromal co-culture data, we found that GDC-0853 mitigated 
survival in response to these stimulatory factors (Figure 2C). GDC-0853’s ability to maintain 
cytotoxicity in the presence of these activators demonstrates that it exerts broad efficacy across 
many stimulatory receptors.    
TLR9 recognizes unmethylated CpG antigens commonly found in bacterial DNA. Stimulation by 
this nonspecific molecular pattern initiates a BTK dependent signaling cascade which results in 
B cell activation. Surface expression of CD86 is increased following ligation of TLR9 with CpG 
and is a common means of measuring B cell activation. We found that increases in CD86 
expression induced by CpG are decreased 40% following treatment with GDC-0853 (Figure 3). 
This effect was similar to ibrutinib and demonstrates that GDC-0853 limits the activation of 
malignant B cells in CLL.  
GDC-0853 inhibits C481S BTK mutants 
Mutation of its C481 BTK binding site is the most common acquired form of resistance to 
ibrutinib. Plasmids containing wild type or C481S BTK were stably transfected into HEK 293T 
cell lines. As expected, ibrutinib was only able to inhibit wild-type BTK and was ineffective 
against the C481S mutated BTK variant (Figure 4). However, GDC-0853 was found to inhibit 
both wild-type and C481S mutated BTK to a similar degree. 
GDC-0853 lacks ITK inhibition and preserves NK cell mediated ADCC 
In much the same way that B lymphocytes rely upon BTK to promote survival and activation, T 
and NK cells rely upon ITK and other Tec family kinases to elicit their cytotoxic effects. 
Stimulation through the T cell receptor (TCR) constituent CD3 and the co-stimulatory molecule 
CD28 provides a potent activating signal in T cells. IKBa is phosphorylated following TCR 
stimulation resulting in nuclear translocation of NFAT and subsequent changes in gene 
expression. Because of its unique BTK binding site we hypothesized that, in contrast to ibrutinib, 
GDC-0853 would lack recognition of the conserved Tec family kinase domain which ibrutinib 
nonspecifically targets. This would be expected to spare the function of T and NK cells.  In 
healthy donor T cells, ibrutinib inhibits the phosphorylation of IKBa and NFAT nuclear 
localization. Treatment with GDC-0853, however, preserves T cell activation following TCR 
stimulation (Figure 5A).  
Antibody therapies have been used to prolong patient survival in CLL for decades. However, 
combinations of ibrutinib with anti-CD20 antibodies like rituximab have not been shown to be 
more effective than ibrutinib alone. This is presumably due to ibrutinib rendering antibody 
therapy ineffective through its inhibition of ITK. Knowing that GDC-0853 preserves ITK 
activity in T cells, we tested whether GDC-0853 would be effective in combination with 
antibody therapies. We found significant differences in antibody mediated NK cell ADCC 
between GDC-0853 and ibrutinib (Figure 5B). Combinations of GDC-0853 with alemtuzumab, 
rituximab, ofatumumab, and obinutuzumab possessed 24.8, 27.8, 28.3, and 26.1 percent greater 
absolute cytotoxicity compared to ibrutinib, respectively.  
Discussion 
BTK inhibition has been shown to be a successful therapeutic strategy in CLL as well as other B 
cell malignancies. As the clinical usage of BTK inhibitors continues to increase, so does the 
incidence of resistance and need for alternative therapies. Therefore, developing BTK inhibitors 
like GDC-0853 with unique modes of action is of high importance.  Herein, we have described a 
novel BTK inhibitor with a unique BTK binding site that has the potential to circumvent 
resistance to ibrutinib and combine successfully with antibodies.  
Comparable to the established BTK inhibitor ibrutinib, GDC-0853 inhibits BTK mediated 
functions contributing to CLL pathology. GDC-0853 effectively blocks BCR mediated survival 
signaling via its direct repression of BTK and indirect inhibition of PLCg2, AKT, and ERK. By 
targeting these anti-apoptotic targets, GDC-0853 is expected to reduce survival in primary CLL 
cells. Indeed, we were able to show that GDC-0853 is directly cytotoxic in vitro to primary CLL 
B cells. Furthermore, we have shown that this compound maintains cytotoxicity even in models 
of the protective bone marrow microenvironment. Cytotoxicity in HS5 co-culture experiments 
indicates that our investigational compound may directly abrogate important cytokine induced 
survival. In addition to inhibition of the BCR pathway and direct cytotoxicity, BTK inhibitors 
also reduce the activation of CLL B cells via inhibition of TLR signaling. GDC-0853 was able to 
inhibit CLL activation at a level comparable to ibrutinib, indicating that this compound may be 
an effective clinical BTK inhibitor.  
Resistance to ibrutinib is recurrently mediated by mutation of its C481 BTK binding site. Most 
commonly, this takes the form of a C481S missense mutation which converts ibrutinib from a 
potent irreversible inhibitor to a low potency reversible inhibitor. Due to its distinct site of 
action, GDC-0853 was hypothesized to be effective in C481S mutated BTK variants, and we 
show this to be the case in vitro. Critically, there is data to suggest that even in the presence of 
the C481S mutation, the BCR pathway remains functional, therefore there is rationale to target 
the mutation with an alternative BTK inhibitor such as GDC-0853.  Given that patients who 
develop resistance to ibrutinib experience rapid disease progression the need for effective 
therapies in these populations is great. Our data provide evidence that BTK inhibition can still be 
achieved even in the context of ibrutinib resistance in patients. 
CD20 monoclonal antibody therapies are known to increase survival in CLL when combined 
with active agents, so the combination of a BTK inhibitor with a CD20 monoclonal antibody is 
appealing. Ibrutinib in combination with clinically relevant antibodies used in CLL has been 
effective, but it is unclear whether the combination is superior to single agent therapy, and in 
vitro data suggests that it should not be.  By simultaneously blocking BTK mediated survival 
signaling and actively promoting CLL clearance through immune effector cells, combinations of 
GDC-0853 with antibody therapy may be more synergistic than combinations with ibrutinib. 
While it has been proposed that ITK inhibition by ibrutinib may be beneficial due to the 
suppression of immunosuppressive Th2 responses, proof that ibrutinib potentiates beneficial Th1 
responses is lacking. The consequences of BTK specific and ITK specific inhibition on CLL 
biology warrant further investigation. 
GDC-0853 represents an exciting development in BTK directed therapy. This compound 
performs comparably to ibrutinib in terms of its ability to mitigate BCR signaling, CLL survival, 
and B cell activation. Additionally, we have validated the potential of circumventing ibrutinib 
resistance by inhibiting an allosteric BTK binding site. Due to its novel site of action, GDC-0853 
possesses fewer alternative targets thereby preserving T cell activation and NK cell mediated 
ADCC. These data show for the first time the potential of reversible BTK inhibitor therapy and 
justify further investigation into GDC-0853 and related agents.   
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Figure 1. BCR signaling is inhibited by GDC-0853 Lysate from 1E7/mL primary CLL cells 
were treated with BTK inhibitor or DMSO for 1 hour.  After stimulation, total lysates were 
subjected to SDS-PAGE to investigate BCR signaling. (A) The representative sample 
demonstrates nanomolar inhibition of BTK and PLCg2 and dose dependent decreases in the 
activation of AKT and ERK. (B-E) Densitometry data from five CLL patients were combined to 
compose average patterns of activation by anti-IgM and repression by BTK inhibitor. Ibrutinib 
was used as a positive control to model BTK inhibition.  
Figure 2. GDC-0853 is directly cytotoxic to CLL B cells and limits stromal induced survival 
Cultures of 1E7/mL primary CLL cells treated with 1um BTK inhibitor or DMSO were 
maintained in 10% complete RPMI media for 48hrs and assessed for viability. (A) The raw CLL 
viability was determined by 7AAD staining and read by flow cytometry (N=16). (B) GFP-HS5 
stromal cells were plated and permitted to reach 50-75% confluence before being co-cultured 
with 1E7/mL primary CLL. Both populations were then drugged and viability was measured at 
48hrs (N=9). (C) BTK inhibitor treated CLL cells at 1E7/mL were stimulated by 10ug/mL 
soluble anti-IgM, 1ug/mL CD40L, or 50ng/mL BAFF for 48hrs (N=8). Viability was normalized 
to an unstimulated vehicle condition.  
Figure 3.  TLR mediated activation is reduced by GDC-0853 1E7/mL primary CLL cells 
were treated with BTK inhibitor and stimulated with 3.2ug/mL of CpG-ODN (N=15). After 
48hrs cells were stained with CD86-PE antibody and measured for fluorescence by flow 
cytometry. MFI results were normalized to untreated and unstimulated paired samples.  
Figure 4.  GDC-0853 effectively inhibits both wild type and C481S mutated BTK variants 
The HEK 293T BTK null cell line was stably transfected with either wild type or C481S mutated 
BTK. Following BTK inhibitor treatment these cell lines were lysed and subjected to SDS-
PAGE analysis.  
Figure 5.  ITK dependent activation of T and NK cells is preserved by GDC-0853 (A) 
Following 1 hour treatment with BTK inhibitor or vehicle, 1E6/mL healthy human T cells were 
activated by antiCD3/antiCD28 stimulation. Nuclear and cytosolic lysates were collected and 
analyzed by SDS-PAGE. (B) Cr51 labeled CLL B cells treated with antibody therapies were co-
cultured with BTK inhibitor treated NK cells at a target to effector ratio of 1:25. Following four 
hours of lysis supernatant from these co-cultures was collected and analyzed for levels of 
radioactive Cr51. 2 separate CLL patients were each co-cultured with 2 allogenic NK cell donors 









































Figure 1. BCR signaling is inhibited by GDC-0853 




































































































































































































































































































































































































































































































Figure 5.  ITK dependent activation of T and NK cells is preserved by GDC-0853 
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